Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Cash from Investing Activities for 12 consecutive years, with $38.4 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Investing Activities fell 59.22% year-over-year to $38.4 million; the TTM value through Mar 2026 reached $234.3 million, up 993.05%, while the annual FY2025 figure was $290.0 million, 231.97% up from the prior year.
  • Cash from Investing Activities hit $38.4 million in Q1 2026 for Syndax Pharmaceuticals, down from $81.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $94.1 million in Q1 2025 and bottomed at -$269.0 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is $2.4 million, with a median of $38.4 million recorded in 2026.
  • Year-over-year, Cash from Investing Activities skyrocketed 689.97% in 2023 and then crashed 1551.15% in 2024.
  • Syndax Pharmaceuticals' Cash from Investing Activities stood at -$137.6 million in 2022, then skyrocketed by 88.16% to -$16.3 million in 2023, then plummeted by 1551.15% to -$269.0 million in 2024, then surged by 130.33% to $81.6 million in 2025, then plummeted by 52.94% to $38.4 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $38.4 million, $81.6 million, and $72.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.